Leveraging quantitative systems pharmacology and artificial intelligence to advance treatment of chronic kidney

Adam Gaweda1,2, Michael Brier1,2, Eleanor Lederer2,3,4

  • 1Robley Rex Veterans Affairs Medical Center, Louisville, Kentucky, United States.

Insights

Targeting abnormal mineral movement in chronic kidney disease mineral bone disorder (CKD-MBD) shows promise. This approach, using AI and mathematical modeling, may improve patient outcomes beyond current guidelines.

Area of Science:

  • Nephrology
  • Systems Biology
  • Artificial Intelligence in Medicine

Background:

  • Chronic kidney disease mineral bone disorder (CKD-MBD) is linked to increased cardiovascular mortality in CKD patients.
  • Current therapeutic strategies, guided by Kidney Disease: Improving Global Outcomes (KDIGO), inadequately improve clinical outcomes.
  • This may be due to targeting surrogate biochemical markers rather than the underlying pathophysiology.

Purpose of the Study:

  • To test a novel therapeutic approach for CKD-MBD using a Systems Biology Approach.
  • To investigate targeting abnormal mineral flux (movement from bone to soft tissue) using machine learning and mathematical modeling.
  • To compare the efficacy of targeting mineral flux versus standard KDIGO guidelines.

Main Methods:

  • Developed a mathematical model simulating calcium and phosphate movement between body compartments.
  • Applied reinforcement learning (RL), a machine learning technique, to explore therapeutic scenarios.
  • Simulated four scenarios: standard KDIGO, RL achieving KDIGO, RL targeting mineral flux (RLFLUX), and a combined approach (RLKDIGOFLUX).

Main Results:

  • Explicitly targeting abnormal mineral flux significantly reduced mineral movement compared to the standard KDIGO approach.
  • The RLFLUX approach achieved acceptable biochemical outcomes while minimizing abnormal mineral flux.
  • Simulations highlighted limitations of targeting secondary hyperparathyroidism and the critical role of phosphate homeostasis.

Conclusions:

  • Current CKD-MBD therapies targeting surrogate markers like secondary hyperparathyroidism are limited.
  • Deranged phosphate homeostasis plays a central role in the development of CKD-MBD.
  • AI combined with mathematical modeling offers a feasible platform for rapidly testing novel therapeutic hypotheses in silico for CKD-MBD.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
74
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
172
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
180
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697